Abraxane Combined With Xeloda as Neo-Adjuvant Chemotherapy in Early Breast Cancer

Summary

Some studies have demonstrated the efficacy of Abraxane in treating breast cancer in both adjuvant and metastatic settings. Few data is available on Abraxane in neoadjuvant treatment for breast cancer. The aim of this project is to evaluate tailored primary systemic therapy with weekly Abraxane (125mg/m2) Combined With Q3week Xeloda (1250mg/m2) in early operable (stage of T2-4N0-3M0) breast cancer. This study will be an open label non randomized, single arm, single center study.

Timeline

Start

2018-12-01

Primary completion

2020-09-30

Completion

2020-09-30

Drugs

Indications